Researchers from A*STAR's Institute of Molecular and Cell Biology (IMCB) and National Cancer Centre Singapore (NCCS) have discovered how the loss of a gene, PBRM1, can lead to the development of kidney cancer. The work is ...
Jul 28, 2023
0
54
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive ...
Jun 26, 2023
0
133
Dr. Niklas Klümper, resident at the Department of Urology of the University Hospital Bonn (UKB) and working group leader at the Institute for Experimental Oncology (IEO), and Dr. Jonas Saal, resident at the Medical Clinic ...
Jun 22, 2023
0
29
A team led by the National Cancer Centre Singapore (NCCS) with members from Singapore General Hospital, A*STAR's Institute of Molecular and Cell Biology (IMCB) and Genome Institute of Singapore (GIS), National University ...
Jun 7, 2023
0
6
Outcomes for patients with clear cell renal cell carcinoma have improved over the past decade due to the approval of immunotherapies, yet still there is a subset of patients who do not respond to this type of therapy.
Apr 26, 2023
0
24
Little is known about how radiation therapy to kill cancer cells affects immune cells and other components of patient tumors. But a study out of Roswell Park Comprehensive Cancer Center is shedding light on that process, ...
Apr 25, 2023
0
2
In a new study, researchers from The University of Texas MD Anderson Cancer Center have created the largest single-cell atlas of brain metastases from renal cell carcinoma (RCC) with matched primary and extracranial metastases, ...
Apr 18, 2023
0
1
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), ...
Apr 17, 2023
0
2
Immunotherapies, such as anti-PD-1 and anti-PD-L1, have become standard first line therapies for patients with advanced renal cell carcinoma (kidney cancer). Most patients, however, eventually experience disease progression, ...
Apr 3, 2023
0
4
For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The Lancet ...
Mar 13, 2023
0
6
